Status:
COMPLETED
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
Lead Sponsor:
Pfizer
Conditions:
Ejaculation
Eligibility:
MALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Assessment of efficacy and safety UK-390,957
Eligibility Criteria
Inclusion
- Premature ejaculation as defined by DSM-IV
Exclusion
- History of erectile dysfunction
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00219635
Start Date
January 1 2005
End Date
July 1 2005
Last Update
November 7 2012
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States
2
Pfizer Investigational Site
San Bernardino, California, United States
3
Pfizer Investigational Site
Metairie, Louisiana, United States
4
Pfizer Investigational Site
Watertown, Massachusetts, United States